Tempest Therapeutics, Inc.

NASDAQ (USD): Tempest Therapeutics, Inc. (TPST)

Last Price

1.24

Today's Change

-0.01 (0.80%)

Day's Change

1.23 - 1.31

Trading Volume

365,298

Overview

Market Cap

31 Million

Shares Outstanding

25 Million

Avg Volume

3,011,545

Avg Price (50 Days)

1.69

Avg Price (200 Days)

3.17

PE Ratio

-0.77

EPS

-1.60

Earnings Announcement

06-Nov-2024

Previous Close

1.25

Open

1.26

Day's Range

1.23 - 1.31

Year Range

0.17 - 9.77

Trading Volume

365,298

Price Change Highlight

1 Day Change

-0.80%

5 Day Change

-0.80%

1 Month Change

-7.46%

3 Month Change

-60.13%

6 Month Change

-63.42%

Ytd Change

-71.88%

1 Year Change

202.51%

3 Year Change

-91.35%

5 Year Change

-98.38%

10 Year Change

-99.96%

Max Change

-99.93%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment